MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. MyoKardia’s initial focus is on small molecule therapeutics aimed at the myocardium to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction.
Additional Info
ACC.20/WCC Learning Pathways? (select all that apply)
Heart Failure and Cardiomyopathies